Gujarat Themis Biosyn Achieves Rs 4,668 Lakhs Annual Profit, Recommends Dividend

Gujarat Themis Biosyn Limited announced strong financial results for the fiscal year and fourth quarter ending March 31, 2026. The company reported a full-year net profit of Rs 4,668.15 lakhs on total income of Rs 16,825.09 lakhs, with earnings per share (EPS) at Rs 4.28.

The fourth quarter also showed robust performance, with net profit reaching Rs 1,089.12 lakhs on a total income of Rs 4,515.41 lakhs.

Shareholder Value and Future Growth

The company's consistent profitability throughout the year and in the final quarter highlights its stable financial health. Shareholders are set to benefit from a recommended final dividend of Re 0.67 per equity share. Additionally, Gujarat Themis Biosyn is planning a preferential equity issue to raise capital from non-promoters. This move is expected to support future expansion or operational enhancements.

Company Background

Operating in the pharmaceutical sector, Gujarat Themis Biosyn has a track record of consistent operations, with a focus on biosimilars and active pharmaceutical ingredients. The recent financial year's results reflect its established market presence and ongoing business activities.

Key Changes and Compliance

Shareholders will receive the announced final dividend, pending necessary approvals. The preferential issue is also subject to approvals and aims to strengthen the company's balance sheet. The appointment of a new Cost Auditor ensures the company is prepared for the upcoming financial year's compliance requirements.

New Labor Codes Impact

Gujarat Themis Biosyn has recognized a potential incremental financial impact of Rs 14.49 lakhs due to the implementation of new Labour Codes, effective from November 2025. While this cost is minor relative to the overall profit, it introduces a new expense factor for the company.

Financial Highlights (FY26)

• Annual Total Income: Rs 16,825.09 Lakhs
• Annual Net Profit: Rs 4,668.15 Lakhs
• Annual EPS: Rs 4.28
• Q4 FY26 Total Income: Rs 4,515.41 Lakhs
• Q4 FY26 Net Profit: Rs 1,089.12 Lakhs
• Recommended Final Dividend: Re 0.67 per equity share

Investor Focus Areas

Moving forward, investors will likely focus on the progress and finalization of the preferential equity issue and its effect on the company's capital structure. Monitoring how Gujarat Themis Biosyn manages costs, particularly in light of the new Labour Codes, will also be crucial.